Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Market Closed 06-26 16:00:00 EDT

7.13

-1.08

-13.15%

盘后7.36

+0.23+3.29%

19:59 EDT

High8.43	Low6.75	Vol7.42M
Open8.22	D1 Closing8.21	Amplitude20.46%
Mkt Cap195.31M	Tradable Cap168.08M	Total Shares27.39M
T/O53.13M	T/O Rate31.48%	Tradable Shares23.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":7.13,"timestamp":1782504000000,"preClose":8.21,"halted":0,"volume":7420398,"hourTrading":{"tag":"盘后","latestPrice":7.3643,"preClose":7.13,"latestTime":"19:59 EDT","volume":226525,"amount":1617036.2523,"timestamp":1782518373060,"change":0.2343,"changeRate":0.032861,"amplitude":0.070505},"delay":0,"changeRate":-0.1315468940316688,"floatShares":23574200,"shares":27393027,"eps":-2.108803,"marketStatus":"Market Closed","change":-1.08,"latestTime":"06-26 16:00:00 EDT","open":8.22,"high":8.43,"low":6.75,"amount":53133158.826762,"amplitude":0.204629,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.108803,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1782720000000},"marketStatusCode":7,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":8.21,"preHourTrading":{"tag":"盘前","latestPrice":8.2,"preClose":8.21,"latestTime":"09:28 EDT","volume":12757,"amount":106493.382123,"timestamp":1782480516785,"change":-0.01,"changeRate":-0.001218,"amplitude":0.064555},"postHourTrading":{"tag":"盘后","latestPrice":7.3643,"preClose":7.13,"latestTime":"19:59 EDT","volume":226525,"amount":1617036.2523,"timestamp":1782518373060,"change":0.2343,"changeRate":0.032861,"amplitude":0.070505},"volumeRatio":4.455738515580491,"impliedVol":3.0677,"impliedVolPercentile":0.975},"requestUrl":"/m/hq/s/UNCY","defaultTab":"news","newsList":[{"id":"2646617953","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Pfizer (PFE) and Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2646617953","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646617953?lang=en_us&edition=fundamental","pubTime":"2026-06-27 00:50","pubTimestamp":1782492617,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pfizer (PFE) and Unicycive Therapeutics (UNCY). Pfizer (PFE) In a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pfizer-pfe-and-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-pfizer-pfe-and-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SG9999001176.USD","IE00B19Z3581.USD","UNCY","LU0456855351.SGD","IE00BLSP4452.SGD","BK4539","SG9999001176.SGD","BK4568","LU0985481810.HKD","BK4581","BK4599","BK4007","LU0321505868.SGD","SG9999002224.SGD","IE000M9KFDE8.USD","BK4533","BK4588","LU1066053197.SGD","LU1066051498.USD","LU1894683348.USD","IE0002270589.USD","LU0321505439.SGD","LU1883839398.USD","LU2596442595.SGD","LU0868494617.USD","IE00BLSP4239.USD","LU0225284248.USD","SG9999013999.USD","PFE","BK4534","LU0234572021.USD","LU0058720904.USD","LU1057294990.SGD","SG9999003800.SGD","LU1023059063.AUD","LU0170899867.USD","BK4139","LU1894683264.USD","BK4550","LU0306807586.USD","SGXZ57979304.SGD","LU0225771236.USD","BK4592","LU0122379950.USD","LU0306806265.USD","LU0289739699.SGD","SG9999011175.SGD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","BK4585","IE00B3T34201.USD","SG9999002232.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645259690","title":"Unicycive Therapeutics shareholders ratified Grassi & Co. as auditor for fiscal 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2645259690","media":"Reuters","labels":["executive","event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2645259690?lang=en_us&edition=fundamental","pubTime":"2026-06-22 18:06","pubTimestamp":1782122787,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics held its annual shareholder meeting on June 19, 2025.Shareholders selected three director nominees to serve through the 2027 annual meeting.Shareholders ratified Grassi & Co. CPAs, P.C. as independent registered public accounting firm for the fiscal year ended Dec. 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260622:nNDL6r7TKm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UNCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641260128","title":"Unicycive Expands At-The-Market Equity Offering Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2641260128","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641260128?lang=en_us&edition=fundamental","pubTime":"2026-06-06 05:46","pubTimestamp":1780696010,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. Unicycive Therapeutics, Inc. expanded its existing at-the-market equity program orig...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/unicycive-expands-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/unicycive-expands-at-the-market-equity-offering-program?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4588","BK4539","BK4215","EQR","BK4585","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140475","title":"Unicycive Therapeutics Raises ATM Offering of Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140475","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140475?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:58","pubTimestamp":1780693112,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics  said late Friday it has increased the number of shares that may be sold in an \"at-the-market\" offering with Guggenheim Securities to $150 million.Its previous sales agreement was to sell shares of up to $100 million from time to time through the ATM offering, according to its regulatory filing. The firm said it has filed a shelf registration statement for the offering.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","UNCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641140308","title":"BRIEF-Unicycive Therapeutics - Files Base Prospectus To Offer Up To $150 Million In Securities - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641140308","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641140308?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:35","pubTimestamp":1780691758,"startTime":"0","endTime":"0","summary":"BRIEF-Unicycive Therapeutics - Files Base Prospectus To Offer Up To $150 Million In Securities - SEC FilingJune 5  - Unicycive Therapeutics Inc UNCY.O:UNICYCIVE THERAPEUTICS - FILES BASE PROSPECTUS TO OFFER UP TO $150 MILLION IN SECURITIES - SEC FILINGUNICYCIVE THERAPEUTICS - FILES SALES AGREEMENT PROSPECTUS TO OFFER UP TO $50 MILLION OF COMMON STOCK - SEC FILINGSource text: [ID:n0001213900-26-065819]Further company coverage: UNCY.O ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0AV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641068147","title":"Unicycive Therapeutics files $150M mixed securities shelf","url":"https://stock-news.laohu8.com/highlight/detail?id=2641068147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641068147?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:20","pubTimestamp":1780690810,"startTime":"0","endTime":"0","summary":"16:18 EDT Unicycive Therapeutics (UNCY) files $150M mixed securities shelf Published first on TheFly – the ultimate source for real-time, market-mo...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-files-150m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-files-150m-mixed-securities-shelf-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641757147","title":"Unicycive Therapeutics - Files Sales Agreement Prospectus to Offer up to $50 Mln of Common Stock - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2641757147","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641757147?lang=en_us&edition=fundamental","pubTime":"2026-06-06 04:17","pubTimestamp":1780690640,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260605:nFWN42D0AV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641097167","title":"Unicycive publishes corporate presentation on OLC hyperphosphatemia treatment for dialysis patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2641097167","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2641097167?lang=en_us&edition=fundamental","pubTime":"2026-06-05 05:16","pubTimestamp":1780607789,"startTime":"0","endTime":"0","summary":"Unicycive highlighted oxylanthanum carbonate  as its lead program for hyperphosphatemia in chronic kidney disease patients on dialysis.OLC NDA is under FDA review with a June 29, 2026 PDUFA date following a late-December 2025 resubmission.Prior CRL cited a single deficiency tied to compliance status at a third-party manufacturing vendor; a Type A FDA meeting was held in late 2025.Presentation framed hyperphosphatemia as a US market opportunity of more than $1 billion.Unicycive projected cash runway into 2027 to support a potential OLC approval and launch.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief on June 04, 2026, and is solely responsible ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260604:nNDL8L8HCK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640941783","title":"Unicycive Therapeutics Is Maintained at Speculative Buy by Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2640941783","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640941783?lang=en_us&edition=fundamental","pubTime":"2026-06-02 23:11","pubTimestamp":1780413060,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 02, 2026 11:11 ET (15:11 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638692306","title":"Unicycive Therapeutics management to meet virtually with Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2638692306","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638692306?lang=en_us&edition=fundamental","pubTime":"2026-05-28 23:05","pubTimestamp":1779980739,"startTime":"0","endTime":"0","summary":"Virtual Meeting to be held on May 29 hosted by Piper Sandler. Published first on TheFly – the ultimate source for real-time, market-moving breaking...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-management-to-meet-virtually-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-management-to-meet-virtually-with-piper-sandler-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635647050","title":"Assessing Unicycive Therapeutics (UNCY) Valuation As Q1 Loss Widens And FDA Decision On OLC Nears","url":"https://stock-news.laohu8.com/highlight/detail?id=2635647050","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635647050?lang=en_us&edition=fundamental","pubTime":"2026-05-16 14:40","pubTimestamp":1778913646,"startTime":"0","endTime":"0","summary":"Why Unicycive Therapeutics (UNCY) is Back on Investors’ Radar\nUnicycive Therapeutics (UNCY) has drawn fresh attention after reporting its first quarter 2026 results, showing a net loss of $12.82 million alongside ongoing FDA review of oxylanthanum carbonate with a June 29, 2026 PDUFA date.\nThis combination of a wider quarterly loss, preparations for a possible oxylanthanum carbonate launch, and a defined regulatory decision date is shaping how investors are reassessing the stock’s risk and...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-uncy/unicycive-therapeutics/news/assessing-unicycive-therapeutics-uncy-valuation-as-q1-loss-w","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LABU","BK4139","BK4588","BK4539","BK4585","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635476697","title":"Unicycive Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635476697","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635476697?lang=en_us&edition=fundamental","pubTime":"2026-05-14 11:02","pubTimestamp":1778727727,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc reports results for the quarter ended March 31 - Earnings SummaryUnicycive Therapeutics Inc UNCY.OQ reported a quarterly adjusted loss of 54 cents per share for the quarter ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R04K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635754594","title":"Unicycive Therapeutics publishes corporate presentation on kidney disease drug pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2635754594","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635754594?lang=en_us&edition=fundamental","pubTime":"2026-05-14 06:46","pubTimestamp":1778712371,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics highlighted oxylanthanum carbonate  as lead program for hyperphosphatemia in chronic kidney disease patients on dialysis, with an FDA PDUFA date of June 29, 2026, following acceptance of an NDA resubmission.NDA resubmission followed a late 2025 Type A meeting focused on resolving a compliance deficiency tied to a third-party manufacturing vendor cited in a complete response letter.Presentation framed hyperphosphatemia as a US market opportunity of more than USD 1 billion, citing about 550,000 US dialysis patients with roughly 80% receiving phosphate binders.In OLC pivotal safety population , treatment-related adverse events occurring in at least 5% of patients were diarrhea at 9% and vomiting at 6%, with no treatment-related serious adverse events.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pur","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260513:nNDL2gnmRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635384787","title":"Unicycive Therapeutics Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2635384787","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635384787?lang=en_us&edition=fundamental","pubTime":"2026-05-13 22:00","pubTimestamp":1778680800,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 13, 2026 10:00 ET (14:00 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634821639","title":"Unicycive Therapeutics Q1 EPS $(0.54) Misses $(0.51) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2634821639","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634821639?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:48","pubTimestamp":1778586480,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (NASDAQ:UNCY) reported quarterly losses of $(0.54) per share which missed the analyst consensus estimate of $(0.51) by 5.88 percent. This is a 8 percent decrease over losses of $(0.50) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52481360/unicycive-therapeutics-q1-eps-0-54-misses-0-51-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634954213","title":"Unicycive Therapeutics Q1 net loss widens on warrant liability","url":"https://stock-news.laohu8.com/highlight/detail?id=2634954213","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634954213?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:12","pubTimestamp":1778584373,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Q1 net loss widens on warrant liabilityOverviewU.S. kidney disease biotech reported Q1 net loss widened mainly due to warrant liability changesR&D expense fell while G&A costs r","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL1N41P0J0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634218702","title":"Unicycive Therapeutics Q1 Income From Operations USD -8.437 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634218702","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634218702?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:05","pubTimestamp":1778583900,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nPLX70D8DB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634138492","title":"Press Release: Unicycive Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2634138492","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634138492?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:05","pubTimestamp":1778583900,"startTime":"0","endTime":"0","summary":"-- U.S. Food and Drug Administration  review of oxylanthanum carbonate.  New Drug Application  resubmission remains on track, with a. Prescription Drug User Fee Act  target action date of June 29,\"As we approach the June 29th PDUFA target action date, we remain optimistic about the potential approval of OLC and focused on preparations for the subsequent launch of OLC,\" said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. \"Our ongoing dialogue with the FDA during the review cycle has been constructive and timely. Uncontrolled hyperphosphatemia remains a significant health concern, affecting nearly 75% of U.S. patients with chronic kidney disease who are undergoing dialysis. OLC has the potential to improve adherence and phosphorus control with reduced pill burden, compared with currently available phosphate binders.\". a bioequivalence study in healthy volunteers, and a tolerability study in. patients with CKD on dialysis), multiple preclinical studies, and. continues to stren","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4604","LU2237443622.USD","BK4585","LU2237443382.USD","BK4006","LU2746668461.USD","LU1363072403.SGD","BK4183","IE00BFXG1179.USD","UNCY","IE00BKVL7J92.USD","LU2746668974.SGD","IE0009354923.USD","LU2237443978.SGD","BK4139","CMC","BK4588","BK4539","LU2237443465.HKD","LU0971096721.USD","LU0882574139.USD","IE00BZ1G4Q59.USD","LU0170899867.USD","LU0267386448.USD","LU2237443895.HKD","LABU","BK4555","TM","BK4099","LU0149725797.USD","ODD","03160","LU2237443549.SGD","IE00B1BXHZ80.USD","IE00BHPRN162.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634290518","title":"Unicycive swings to Q1 FY26 net loss of $12.82 million; operating expenses rise 6% to $8.44 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2634290518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634290518?lang=en_us&edition=fundamental","pubTime":"2026-05-12 18:32","pubTimestamp":1778581940,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics posted a net loss of USD 12.8 million, swinging from net income of USD 570,000 a year earlier.Operating loss widened 6% to USD 8.44 million as operating expenses climbed 6% to USD 8.44 million.General and administrative expense rose 17% to USD 6.83 million, while research and development expense fell 26% to USD 1.61 million.Other results turned to expense of USD 4.39 million from income of USD 8.56 million on a USD 4.78 million change in fair value of warrant liability.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Unicycive Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDL4f1ZrT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634346391","title":"Unicycive Therapeutics Inc  expected to post a loss of 51 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2634346391","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634346391?lang=en_us&edition=fundamental","pubTime":"2026-05-09 00:16","pubTimestamp":1778256972,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics Inc  expected to post a loss of51cents a share - Earnings Preview Unicycive Therapeutics Inc UNCY.OQ UNCY.O is expected to  show no change in quarterly revenue when it reports  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260508:nL8N41L218:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":0.0409},{"period":"1month","weight":0.0085},{"period":"3month","weight":0.1158},{"period":"6month","weight":0.1746},{"period":"1year","weight":0.2003},{"period":"ytd","weight":0.2357}],"compareEarnings":[{"period":"1week","weight":-0.0238},{"period":"1month","weight":-0.0286},{"period":"3month","weight":0.1497},{"period":"6month","weight":0.056},{"period":"1year","weight":0.1914},{"period":"ytd","weight":0.069}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.078139},{"month":2,"riseRate":0.6,"avgChangeRate":0.088088},{"month":3,"riseRate":0.4,"avgChangeRate":0.59683},{"month":4,"riseRate":0.4,"avgChangeRate":-0.11937},{"month":5,"riseRate":0.4,"avgChangeRate":-0.060546},{"month":6,"riseRate":0,"avgChangeRate":-0.151757},{"month":7,"riseRate":0,"avgChangeRate":-0.103059},{"month":8,"riseRate":0.2,"avgChangeRate":-0.122604},{"month":9,"riseRate":0.6,"avgChangeRate":0.038818},{"month":10,"riseRate":0.8,"avgChangeRate":0.050976},{"month":11,"riseRate":0.6,"avgChangeRate":0.060673},{"month":12,"riseRate":0.4,"avgChangeRate":0.09852}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}